Database analysis identified that miR-126 potentially targets disintegrin and metalloproteinase domain-containing protein 9 (ADAM9), which is highly expressed in pancreatic cancer (Grutzmann et al., 2004). Here, ADAM9 is linked to pancreatic neoplasm.